Related Experiment Video
Updated: May 14, 2026
08:49
Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
Serotonin transporter genotype affects serotonin 5-HT1A binding in primates
Bradley T Christian1, Dustin W Wooten, Ansel T Hillmer
1Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin 53705, USA. bchristian@wisc.edu
Summary
The serotonin transporter gene variation (5-HTTLPR) impacts serotonin 1A receptor binding in rhesus monkeys. Lower binding was observed in s-allele carriers, suggesting a role in neurochemistry.
Area of Science:
- Neuroscience
- Genetics
- Psychiatry
Background:
- Serotonin system disruption is linked to anxiety and depression.
- A functional variation in the serotonin transporter promoter gene (5-HTTLPR) may predispose individuals to these illnesses.
- Previous studies on 5-HTTLPR and serotonin transporter binding have yielded inconsistent results, but effects on 5-HT(1A) receptor binding have been noted in humans.
Purpose of the Study:
- To investigate the relationship between 5-HTTLPR genotypes and 5-HT(1A) receptor binding in rhesus monkeys.
- To determine if the 5-HTTLPR polymorphism influences serotonin neurochemistry in a nonhuman primate model.
Main Methods:
- Positron Emission Tomography (PET) imaging using [(18)F]mefway was performed on 58 rhesus monkeys.
- Subjects were genotyped for the 5-HTTLPR polymorphism (33 l/l, 25 s-carriers).
- 5-HT(1A) receptor-specific binding was quantified in cortical and raphe regions.
Main Results:
- Significantly lower 5-HT(1A) receptor binding was observed in s-carrier subjects compared to l/l subjects.
- This reduction in binding was consistent across both cortical brain regions and the raphe nuclei.
- The findings indicate that the 5-HTTLPR polymorphism influences the serotonin neurochemical system.
Conclusions:
- The 5-HTTLPR functional polymorphism significantly affects 5-HT(1A) receptor binding in rhesus monkeys.
- Rhesus monkeys serve as a valuable model for studying the neurobiological effects of the 5-HTTLPR variant.
- This research supports the potential of nonhuman primates in investigating gene-environment interactions related to the serotonin system and behavior.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.